Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the

  Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing
  Protease Inhibitor ABT-450 to be Presented at the European Association for
  the Study of the Liver (EASL) Meeting

Business Wire

WATERTOWN, Mass. -- March 24, 2014

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused
biotechnology company dedicated to creating small molecule drugs in the
infectious disease field, today announced eight studies have been accepted for
presentation at the International Liver Congress (ILC), which is the 49th
Annual Meeting of the European Association for the Study of the Liver (EASL)
taking place in London April 9-12, 2014. These presentations will report
results of regimens containing ABT-450, Enanta’s lead protease inhibitor for
hepatitis C virus (HCV) identified in its ongoing collaboration with AbbVie.
Abstracts can now be viewed at the EASL website at www.easl.eu.

Following is a list of ABT-450-related presentations:

Oral Presentations:

  *SAPPHIRE-II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week
    Regimen of ABT-450/r/ABT-267, ABT-333 and Ribavirin in
    Treatment-Experienced Adults with Hepatitis C Virus in Genotype-1
    S. Zeuzem, et al., April 10, 2014, 14:00-14:15 BST
  *Results from the Phase 2 PEARL-I Study: Interferon-Free Regimens of
    ABT-450/r + ABT-267 with or without Ribavirin in Patients with HCV
    Genotype 4 Infection
    C. Hezode, et al., April 11, 2014, 09:45-10:00 BST
  *SAPPHIRE-I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week
    Regimen of ABT-450/r/ ABT-267, ABT-333 and Ribavirin in 631
    Treatment-Naïve Adults with Hepatitis C Virus in Genotype-1
    JJ Feld, et al., April 11, 2014, 10:15-10:30 BST
  *Results of the Phase 2 Study of M12-999: Interferon-Free Regimen of
    ABT-450/r/ABT-267+ABT-333+ Ribavirin in Liver Transplant Recipients with
    Recurrent HCV Genotype 1 Infection
    P. Kwo, et al., April 12, 10:15-10:30 BST

Poster Presentations:

  *P783 – Serum MIR-122 May Serve as a Biomarker for Response to Direct
    Acting Antivirals: Effect of ABT-450/r with ABT-333 or ABT-267 on MIR-122
    in HCV-Infected Subjects
    J.F. Waring, et al., April 11, 2014, 09:00 – 18:00 BST
  *P1230 – Lack of Impact of Baseline Resistance- Associated Variants (RAVS)
    on Treatment Outcome in the Aviator Study with ABT-450/r, ABT-333, and
    ABT-267 +/- Ribavirin
    P. Krishnan, et al., April 12, 2014, 09:00 – 18:00 BST

Late-Breaker Oral Presentation:

  *TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype
    1-Infected Adults with Compensated Cirrhosis Treated with
    ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)
    F. Poordad, et al. April 12, 2014, 15:30-15:45 BST

Late-Breaker Poster Presentation:

  *P# 1299 – PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in
    >99% of 410 Treatment-Naïve HCV Genotype 1b-Infected Adults With or
    Without Ribavirin
    P. Ferenci, et al. April 12, 2014, 09:00-18:00 BST

About ABT-450

ABT-450 is an NS3 protease inhibitor discovered through Enanta’s collaboration
with AbbVie. AbbVie and Enanta have an agreement to collaborate on the
discovery, development and commercialization of HCV NS3 and NS3/4A protease
inhibitors. Protease inhibitors play an essential role in the viral life cycle
of the hepatitis C virus (HCV). Inhibition of the protease prevents
non-structural (NS) proteins from forming and thereby prevents replication and
survival of the HCV virus. ABT-450 is part of AbbVie’s investigational regimen
for HCV that consists of boosted protease inhibitor ABT-450/ritonavir
(referred to as ABT-450/r), NS5A inhibitor ABT-267 and non-nucleoside
polymerase inhibitor ABT-333.

About Hepatitis C Virus (HCV)

Hepatitis C is a liver disease affecting over 170 million people worldwide.
The virus is typically spread through direct contact with the blood of an
infected person. Hepatitis C increases a person’s risk of developing chronic
liver disease, cirrhosis, liver cancer and death. Patients with compensated
cirrhosis have a liver that is heavily scarred but that can still perform many
important bodily functions with few or no symptoms. There is an acute need for
new HCV therapies that are safer and more effective for many variants of the
virus.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology
company that uses its robust chemistry-driven approach and drug discovery
capabilities to create small molecule drugs in the infectious disease field.
Enanta is discovering, and in some cases developing, novel inhibitors designed
for use against the hepatitis C virus (HCV). These inhibitors include members
of the direct acting antiviral (DAA) inhibitor classes – protease (partnered
with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of antibiotics,
called Bicyclolides, for the treatment of multi-drug resistant bacteria, with
a focus on developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus) infections.

Contact:

Investors
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.